Citicoline in the treatment of essential tremor

الملخص EN

Objectives : To evaluate the clinical efficacy of Citicoline for the treatment of patients affected by essential tremor.

Methods : The study was conducted in the Neurology Department at King Hussein Medical Centre.

A total of 18 subjects were non-randomly selected and enrolled in the study (8 males, 10 females), with a mean age of 62.6 years.

The primary outcome measure was the degree of tremor compared to baseline as measured by the Clinical Rating Scale for Tremor.

Results : The mean duration of symptoms among the study group was 6 years.

All patients were evaluated at least twice, at enrollment and 8 weeks after starting treatment.

The dose was 2ml twice daily (equivalent to 400mg / daily) taken orally.

Seven subjects showed marked improvement on Clinical Rating Scale for Tremor.

Seven subjects showed moderate improvements, and 2 subjects showed mild improvement, and two subjects showed no change.

The overall improvement in all treated subjects was 89% (T-Value = 8.42, PValue = 0.000).

The main side effects encountered during the treatment period were gastrointestinal symptoms in two subjects (11%), anxiety in one subject (6%), headache in one subject (6%), dizziness in one subject (6%), and insomnia in another (6%).

Conclusion : Citicoline significantly improved essential tremor in this small group of subjects.